This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Part 2 - Preparing for the FDA Panel on Aducanumab: Discussing the Briefing Documents with a Neurologist before the Ad-com

Ticker(s): BIIB

Who's the expert?

Name: Dr Russell Swerdlow - MD

Institution: University of Kansas

  • Director of NIH-funded University of Kansas Alzheimer's Disease Center.
  • Currently manages 300 patients with Alzheimer's disease and very familiar with the Aducanumab public literature.
  • Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.

Interview Goal
During this conversation we will speak to a Neurologist who has reviewed the Briefing documents on Aducanumab.

Are You Interested In These Questions?



Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.